<DOC>
	<DOCNO>NCT00275067</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , arsenic trioxide temozolomide , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving arsenic trioxide temozolomide together radiation therapy surgery may kill remain tumor cell . PURPOSE : This phase I/II trial study side effect best dose arsenic trioxide temozolomide give together radiation therapy see well work treat patient malignant glioma remove surgery .</brief_summary>
	<brief_title>Arsenic Trioxide , Temozolomide , Radiation Therapy Treating Patients With Malignant Glioma That Has Been Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose ( MTD ) arsenic trioxide temozolomide combine radiotherapy patient resect supratentorial malignant glioma . ( Phase I ) - Determine toxicity regimen patient . ( Phase I ) Secondary - Determine 6- 12-month progression-free survival patient treat regimen MTD reach . ( Phase II ) - Determine radiographic response patient treat regimen . ( Phase II ) - Determine safety regimen patient . ( Phase II ) OUTLINE : This phase I , dose-escalation study arsenic trioxide temozolomide follow phase II study . - Phase I : Patients undergo radiotherapy daily 5 day week receive oral temozolomide daily approximately 6½ week . Patients also receive arsenic trioxide IV 1-4 hour daily , 5 day week week 1 twice week week 2-7 . Beginning within 3-5 week completion radiotherapy , patient receive oral temozolomide daily day 1-5 . Treatment temozolomide repeat every 28 day 1 year absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos arsenic trioxide temozolomide maximum tolerate dose ( MTD ) determine . The MTD define dose precede 1 3 2 6 patient experience dose-limiting toxicity . - Phase II : Patients undergo radiotherapy receive arsenic trioxide temozolomide phase I MTD . Patients receive temozolomide phase I 1 year absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically 1 year . PROJECTED ACCRUAL : A total 12-18 patient accrued phase I portion study . A total 25 patient accrue phase II portion study .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm supratentorial malignant glioma 1 follow type : Glioblastoma multiforme Gliosarcoma Anaplastic astrocytoma Anaplastic oligodendroglioma Anaplastic mix gliomas Anaplastic glioma otherwise specify Has undergone surgical resection tumor Patients biopsy eligible Evaluable measurable disease follow resection recurrent tumor mandate entry study No brain metastasis PATIENT CHARACTERISTICS : Karnofsky performance status 60100 % Life expectancy &gt; 3 month WBC &gt; 3,000/mm^3 Absolute neutrophil count &gt; 2,000/mm^3 Platelet count &gt; 100,000/mm^3 Hemoglobin &gt; 10 g/dL ( eligibility level hemoglobin may reach transfusion ) Creatinine ≤ 1.5 mg/dL Bilirubin ≤ 2 mg/dL Transaminases ≤ 2 time upper limit normal Serum potassium* &gt; 4.0 mEq/dL Serum magnesium* &gt; 1.8 mg/dL NOTE : *If serum electrolytes specify limit baseline laboratory test , supplemental electrolyte administer bring serum concentration level administer arsenic trioxide Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month completion study treatment No seconddegree heart block QT interval ≤ 460 msec No malignancy within past 3 year except curatively treat carcinoma situ basal cell carcinoma skin Patients undergo MRI eligible study No serious concurrent infection medical illness would jeopardize ability patient receive therapy protocol reasonable safety PRIOR CONCURRENT THERAPY : See Disease Characteristics Patients must recover effect surgery prior start treatment ( 1014 day minimum ) maintain stable corticosteroid regimen 5 day Concurrent glucocorticoid therapy allow smallest effective dose Patients must nonenzymeinducing anticonvulsant minimize drug reaction No prior radiation therapy , chemotherapy , immunotherapy , therapy biologic agent ( include immunotoxins , immunoconjugates , antisense agent , peptide receptor antagonist , interferon , interleukin , tumorinfiltrating lymphocyte , lymphokineactivated killer cell , gene therapy ) , hormonal therapy brain tumor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>recurrent adult brain tumor</keyword>
</DOC>